此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study in Depression and Associated Painful Physical Symptoms

2012年1月10日 更新者：Eli Lilly and Company

Duloxetine Versus Placebo in the Acute Treatment of Patients With Major Depressive Disorder and Associated Painful Physical Symptoms

The purpose of this study is to find out if 60 mg of duloxetine given once a day by mouth for 8 weeks to patients diagnosed with major depressive disorder, who also report associated painful physical symptoms, is better than placebo when treating depression and its associated painful symptoms.

研究概览

地位

完全的

条件

干预/治疗

研究类型

介入性

注册 (实际的)

527

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 波多黎各
      • Caguas、波多黎各、00725
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • San Juan、波多黎各、00926
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  • 美国
    • California
      • Sherman Oaks、California、美国、91403
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Connecticut
      • Cromwell、Connecticut、美国、06416
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Florida
      • Fort Lauderdale、Florida、美国、33319
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Orlando、Florida、美国、32806
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Georgia
      • Atlanta、Georgia、美国、30308
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Illinois
      • Hoffman Estates、Illinois、美国、60194
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Springfield、Illinois、美国、62711
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Indiana
      • Evansville、Indiana、美国、47714
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Kentucky
      • Florence、Kentucky、美国、41042
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Louisiana
      • Lake Charles、Louisiana、美国、70601
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Massachusetts
      • Belmont、Massachusetts、美国、02478
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Boston、Massachusetts、美国、02135
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Michigan
      • Troy、Michigan、美国、48083
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • New Jersey
      • Toms River、New Jersey、美国、08755
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Willingboro、New Jersey、美国、08046
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • New York
      • Brooklyn、New York、美国、11235
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Rochester、New York、美国、14618
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Staten Island、New York、美国、10305
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Ohio
      • Beachwood、Ohio、美国、44122
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Toledo、Ohio、美国、43623
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73109
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Oregon
      • Portland、Oregon、美国、97210
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Salem、Oregon、美国、97301
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Pennsylvania
      • Allentown、Pennsylvania、美国、18104
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Media、Pennsylvania、美国、19063
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Philadelphia、Pennsylvania、美国、19107
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Rhode Island
      • Lincoln、Rhode Island、美国、02865
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Tennessee
      • Memphis、Tennessee、美国、38119
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Texas
      • Wichita Falls、Texas、美国、76309
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Virginia
      • Richmond、Virginia、美国、23230
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Washington
      • Bellevue、Washington、美国、98007
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Wisconsin
      • Middleton、Wisconsin、美国、53562
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Meets criteria for Major Depressive Disorder (MDD) as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • Montgomery-Asberg Depression Rating Scale (MADRS) total score greater than or equal to 20 during the Screening Phase
  • At least 1 previous episode of depression
  • Painful physical symptoms with a score greater than or equal to 3 on the Brief Pain Inventory-Short Form (BPI-SF) average pain question
  • A Clinical Global Impression of Severity (CGI-S) score greater than or equal to 4 during the Screening Phase
  • Written informed consent

Key Exclusion Criteria:

  • Currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device
  • Have previously completed or withdrawn from this study or any other study investigating duloxetine (unless no study drug was received)
  • Women of child-bearing potential who are not using a medically accepted means of contraception
  • Have any current (within past 6 months) DSM-IV-TR primary Axis I diagnosis other than MDD
  • Have a history of alcohol abuse and/or substance abuse or dependence within 1 year prior to being screened for the study
  • Have any prior history of bipolar disorder, psychosis, or schizophrenia
  • Have an Axis II disorder that would interfere with study compliance
  • Lack of response of any episode of major depression (lifetime of subject) to two or more adequate courses of antidepressant therapy, at a clinically appropriate dose for at least 4 weeks or, alternatively, in the judgment of the investigator, the subject meets criteria for treatment resistant depression
  • Have previously received treatment of MDD or Generalized Anxiety Disorder (GAD) with an adequate trial of duloxetine and did not respond or could not tolerate duloxetine
  • Diagnosis of acute liver injury or severe cirrhosis
  • Uncontrolled narrow-angle glaucoma
  • Positive urine drug screen for any substance of abuse
  • Have a serious medical illness, including any cardiovascular, hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or clinically significant laboratory abnormality that is not stabilized or is anticipated to require intervention, hospitalization, or use of an excluded medication during the study
  • History of a serious suicide attempt or subject judged clinically to be at serious suicidal risk
  • Requires continuous use of analgesics for 6 or more months because of chronic pain
  • Has pain of a known origin
  • Meets criteria for fibromyalgia as defined by the American College of Rheumatology
  • Experiences greater than or equal to 1 migraine headache per week
  • Have had electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or vagus nerve stimulation (VNS) within 1 year prior to being screened for the study
  • Initiating, changing, or stopping psychotherapy within 6 weeks prior to being screened for the study or at any time during the study
  • Investigator or subject anticipates initiating, changing, or stopping non-pharmacologic or alternative therapies for painful physical symptoms at any time during the study
  • Are taking any excluded medications within 7 days prior to randomization with the exception of fluoxetine which cannot be taken within 30 days prior to randomization
  • Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days prior to randomization or have the potential need to use an MAOI during the study or within 5 days after discontinuation of study drug
  • Abnormal thyroid stimulating hormone
  • Has epilepsy or history of seizure disorder or received treatment with anticonvulsant medication for epilepsy or seizures

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：双倍的

武器和干预

参与者组/臂
干预/治疗
安慰剂比较：安慰剂
药品：Placebo
Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
实验性的：度洛西汀
药品：Duloxetine
Participants received 30 milligrams (mg) duloxetine once daily (QD) by mouth (po) for 1 week, followed by 60 mg QD po for 7 weeks. Participants were given the option to take duloxetine 30 mg QD, po for a 2-week taper phase.
其他名称：
  • 欣百达
  • LY248686

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Change From Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Average Pain Score During the 8-Week Treatment Period
大体时间：Day 1 through 8 weeks
A self-reported scale that measures the severity of pain based on the average pain experienced over the past 24 hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). The overall change is based on the estimated main treatment effect. The Least Squares (LS) Mean Value was adjusted for treatment, investigator, visit, baseline, treatment*visit interaction, and baseline*visit interaction.
Day 1 through 8 weeks
Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8
大体时间：Baseline, 8 weeks
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). The Least Squares (LS) Mean Value was adjusted for treatment, investigator, visit, baseline, treatment*visit interaction, and baseline*visit interaction.
Baseline, 8 weeks

次要结果测量

结果测量
措施说明
大体时间
第 8 周 Sheehan 残疾量表 (SDS) 总分和项目分数相对于基线的变化
大体时间：基线，8 周
SDS由参与者完成；用于评估参与者的症状对其工作/社交/家庭生活的影响。 总分范围从 0 到 30；较高的值表示参与者的工作/社交/家庭生活受到更大的干扰。 每个项目的得分范围从 0 到 10，较高的值表示参与者的工作/学校生活（第 1 项）、社交生活/休闲活动（第 2 项）或家庭生活/家庭责任（第 3 项）受到更大的干扰。 针对治疗、研究者、访视、基线、治疗*访视相互作用和基线*访视相互作用调整 LS 平均值。
基线，8 周
第 8 周简要疼痛清单严重程度和干扰评分 (BPI-S/BPI-I) 相对于基线的变化
大体时间：基线，8 周
测量疼痛的严重程度和对功能的干扰。 严重程度分数：每个问题的 0（无疼痛）至 10（剧烈疼痛）。 干扰分数：0（不干扰）到 10（完全干扰）每个问题评估过去 24 小时疼痛对一般活动、情绪、行走能力、正常工作、与他人的关系、睡眠和生活享受的干扰。 平均干扰=单个干扰项的非缺失分数的平均值。 针对治疗、研究者、访视、基线、治疗*访视交互作用和基线*访视交互作用调整的 LS 平均值。
基线，8 周
Change From Baseline in the Percentage of Participants Achieving Remission up to Week 8
大体时间：Baseline, up to 8 weeks
The Montgomery-Asberg Depression Rating Scale (MADRS) is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Remission is defined as achieving a MADRS total score ≤12.
Baseline, up to 8 weeks
Percentage of Participants Achieving Remission up to Week 8
大体时间：Up to 8 weeks
The Montgomery-Asberg Depression Rating Scale (MADRS) is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale from 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Remission is defined as achieving a MADRS total score ≤12 at the last 2 nonmissing visits (for example, visit 3 [week 1] and visit 4 [week 2], or visit 4 [week 2] and visit 5 [week 4], or visit 5 [week 4] and visit 6 [week 8]).
Up to 8 weeks
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 4
大体时间：Baseline, 4 weeks
The MADRS is a rating scale for severity of depressive mood and symptoms. The MADRS has a 10-item checklist. Items are rated on a scale from 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). The Least Squares (LS) Mean Value was adjusted for treatment, investigator, visit, baseline, treatment*visit interaction, and baseline*visit interaction.
Baseline, 4 weeks
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 2
大体时间：Baseline, 2 weeks
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range from 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). The Least Squares (LS) Mean Value was adjusted for treatment, investigator, visit, baseline, treatment*visit interaction, and baseline*visit interaction.
Baseline, 2 weeks
Patient Global Impression of Improvement (PGI-I) Score at Week 8
大体时间：8 weeks
A scale that measures the participant's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). The Least Squares (LS) Mean Value was adjusted for treatment, investigator, visit, and treatment*visit interaction.
8 weeks
Number of Participants With Suicidal Behaviors, Ideations, and Acts Based on the Columbia Suicide Severity Rating Scale (C-SSRS) During the Double-Blind Treatment Phase
大体时间：Baseline through 8 weeks
The C-SSRS captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of participants with suicidal behaviors, ideations, and acts are provided. Suicidal behavior: a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, and completed suicide. Suicidal ideation: a "yes" answer to any 1 of 5 suicidal ideation questions, which includes wish to be dead, and 4 different categories of active suicidal ideation. Suicidal acts: a "yes" answer to actual attempt or completed suicide.
Baseline through 8 weeks

其他结果措施

结果测量
措施说明
大体时间
第 8 周脉率从基线的变化
大体时间：基线，直至第 8 周

第 8 周时脉率相对于基线的变化是主要分析。 对于脉率的主要分析，针对治疗、研究者、基线、治疗*访视交互作用和基线*访视交互作用调整最小二乘法（LS）平均值。

直到第 8 周脉率从基线的变化是二次分析。 LS 平均值针对治疗、研究者和基线进行了调整。
基线，直至第 8 周
收缩压 (SBP) 和舒张压 (DBP) 从基线变化到第 8 周
大体时间：基线，直至第 8 周

第 8 周时 SBP 和 DBP 相对于基线的变化是主要分析。 对于 SBP 和 DBP 的主要分析，针对治疗、研究者、基线、治疗*访视交互作用和基线*访视交互作用调整了最小二乘法 (LS) 平均值。

直到第 8 周 SBP 和 DBP 从基线的变化是二次分析。 LS 平均值针对治疗、研究者和基线进行了调整。
基线，直至第 8 周
体重从基线变化到第 8 周
大体时间：基线，直至第 8 周

第 8 周时体重相对于基线的变化是主要分析。 对于体重的主要分析，针对治疗、研究者、基线、治疗*访视交互作用和基线*访视交互作用调整最小二乘法（LS）平均值。

从基线到第 8 周的体重变化是二次分析。 LS 平均值针对治疗、研究者和基线进行了调整。
基线，直至第 8 周
Number of Participants With Abnormal Laboratory Values During the Double-Blind Treatment Phase - High Creatinine
大体时间：Baseline through 8 weeks
Laboratory assessment of creatinine during the double-blind treatment phase. Normal creatinine ranges for males are 40.00 micromoles per liter (µmol/L) (low) to 110.00 µmol/L (high). Normal creatinine ranges for females are 31.00 µmol/L (low) to 101.00 µmol/L (high).
Baseline through 8 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Eli Lilly and Company

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2010年3月1日

初级完成 (实际的)

2011年3月1日

研究完成 (实际的)

2011年3月1日

研究注册日期

首次提交

2010年2月16日

首先提交符合 QC 标准的

2010年2月16日

首次发布 (估计)

2010年2月18日

研究记录更新

最后更新发布 (估计)

2012年2月13日

上次提交的符合 QC 标准的更新

2012年1月10日

最后验证

2012年1月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 13630
  • F1J-US-HMGU (其他标识符：Eli Lilly and Company)

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

严重抑郁症的临床试验

  • Hospital Universitari Vall d'Hebron Research Institute
    Instituto de Salud Carlos III
    完全的
    肠动力障碍：分钟节律
    小肠运动障碍 (Disorder)
    西班牙
  • Dren Bio
    Novotech Health Holdings Pte. Ltd.
    招聘中
    DR-01 在大颗粒淋巴细胞白血病或细胞毒性淋巴瘤患者中的研究
    侵袭性 NK 细胞白血病 | 肝脾T细胞淋巴瘤 | 肠病相关的T细胞淋巴瘤 | 皮下脂膜炎样 T 细胞淋巴瘤 | 单形性趋上皮性肠 T 细胞淋巴瘤 | 原发性皮肤 Gamma-Delta T 细胞淋巴瘤 | LGLL - 大颗粒淋巴细胞白血病 | 系统性 EBV1 T 细胞淋巴瘤，如果 CD8 阳性 | Hydroa Vacciniforme-Like Lymphoproliferative Disorder | 结外 NK/T 细胞淋巴瘤，鼻型 | 原发性皮肤CD8+侵略性表皮T细胞淋巴瘤 | 细胞毒性PTCL-NOS（CD8+或CD56+和细胞毒性标记） | 皮肤PTCL-NOS（CD8+或CD56+和细胞毒性标记）
    美国, 澳大利亚, 台湾, 法国, 西班牙, 意大利, 香港, 德国, 韩国
  • Memorial Sloan Kettering Cancer Center
    招聘中
    T 细胞淋巴瘤患者登记处
    蕈样肉芽肿 | 塞扎里综合症 | 血管免疫母细胞性T细胞淋巴瘤 | 肝脾T细胞淋巴瘤 | 间变性大细胞淋巴瘤，ALK 阳性 | 结外 NK/T 细胞淋巴瘤，鼻型 | T细胞淋巴瘤 | 未特指的外周 T 细胞淋巴瘤 | 原发性皮肤间变性大细胞淋巴瘤 | 皮下脂膜炎样 T 细胞淋巴瘤 | 肠病相关的T细胞淋巴瘤 | 间变性大细胞淋巴瘤，ALK 阴性 | 单形性趋上皮性肠 T 细胞淋巴瘤 | T 细胞幼淋巴细胞白血病 | T 细胞大颗粒淋巴细胞白血病 | 原发性皮肤 CD8 阳性侵袭性嗜表皮 T 细胞淋巴瘤 | Hydroa Vacciniforme-Like Lymphoproliferative Disorder | NK细胞淋巴瘤 | 侵袭性 NK 细胞白血病 | 成人 T 细胞白血病/淋巴瘤 及其他条件
    美国

Duloxetine的临床试验

搜索类似试验

赞助者和合作者

医疗条件

药物干预

CROs by country

CROs in Ghana

条件

罕见疾病

药物干预

膳食补充剂

赞助者/合作者

地点

3
订阅